Physician profile
Aysha Seeni
NPI 1942333885
$2,173.03
in general payments reported to CMS, 2019-2025
27 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $56.58 · 2021: $46.18 · 2022: $44.17 · 2023: $295 · 2024: $730 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,026.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $421.34 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $414.87 | 2023-2025 | Fasenra, Airsupra, Breztri |
| Novo Nordisk INC | $255.60 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $115.31 | 2024-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $105.71 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.54 | 2022-2025 | Jardiance, Ofev, Jascayd |
| Genzyme Corporation | $88.33 | 2020-2022 | |
| Madrigal Pharmaceuticals | $75.67 | 2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $73.40 | 2024-2025 | |
| Pfizer INC. | $64.37 | 2023-2024 | |
| Harmony Biosciences LLC | $53.05 | 2022-2023 | Wakix |
| Viatris Specialty LLC | $50.34 | 2025 | Yupelri |
| Mylan Specialty L.P. | $49.80 | 2023-2024 | Yupelri |
| Lilly USA, LLC | $43.22 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Electromed, INC. | $35.56 | 2024-2025 | Smartvest |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $32.14 | 2025 | Nuzyra |
| Biosense Webster, INC. | $30.20 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.06 | 2024 | Aralast |
| Endo USA, INC. | $18.93 | 2025 | Aveed |
| Forte Bio-Pharma LLC | $18.04 | 2025 | Prolate, Nalocet, Tanlor |
| Aimmune Therapeutics, INC. | $17.12 | 2023 | |
| Almatica Pharma LLC | $16.19 | 2025 | Teriparatide |
| Genentech USA, INC. | $15.92 | 2024 | Xolair |
| Bavarian Nordic A/S | $15.46 | 2025 | Vivotif |
| Xeris Pharmaceuticals, INC. | $14.21 | 2025 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $13.75 | 2023 | |
| Phathom Pharmaceuticals, INC. | $12.90 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aysha Seeni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.